CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
–News Direct–
CervoMed Inc CEO John Alam joined Steve Darling from Proactive to announce a significant addition to the company's leadership team.
CervoMed has appointed Joshua Boger to its Board of Directors as Chair, leveraging his wealth of experience in drug development and biopharmaceutical leadership to drive the company's strategic initiatives forward.
Dr. Boger is a seasoned industry veteran with over 40 years of experience, renowned for his innovative approach to science and proven track record as a business executive. Currently serving as Executive Chairman of Alkeus Pharmaceuticals, Dr. Boger brings invaluable insights and expertise to CervoMed.
Alam elaborated on the significance of Dr. Boger's appointment and the pivotal phase the company is entering, with topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) expected in the second half of 2024.
Neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, holds immense promise in addressing synaptic dysfunction, particularly in the basal forebrain cholinergic system, which is most impacted in DLB.
Drawing from preclinical studies and clinical trials involving over 300 participants, Alam highlighted neflamapimod's favorable safety profile and its significant impact on dementia severity as demonstrated in the AscenD-LB Phase 2a clinical study.
These promising results underscore the potential of neflamapimod to address the unmet medical needs in DLB and pave the way for transformative treatment options. The appointment of Dr. Boger and the advancements in CervoMed's clinical trials signify a significant milestone in the company's mission to develop innovative therapies for neurodegenerative diseases.
With a visionary leadership team and a promising pipeline of treatments, CervoMed is poised to make a meaningful impact on the lives of patients and caregivers affected by DLB and related conditions. Stay tuned for further updates as CervoMed continues its journey towards advancing neurological healthcare.
Contact Details
Proactive North America
Proactive North America
+1 604-688-8158
NA-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/cervomed-appoints-drug-development-veteran-dr-joshua-boger-as-chairman-of-the-board-922624018
CervoMed
COMTEX_448082051/2655/2024-02-20T10:25:37
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DFHS Newspaper journalist was involved in the writing and production of this article.
